FPS
AIMT

Fieldpoint Private Securities’s Aimmune Therapeutics AIMT Stock Holding History

Fieldpoint Private Securities’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,669
Closed -$183K – 301
2020
Q1 		$183K Sell
12,669
-129
-1% -$3.3K 0.07% 234
2019
Q4 		$429K Buy
12,798
+9,507
+289% +$266K 0.13% 173
2019
Q3 		$69K Buy
+3,291
New +$67.2K 0.03% 349

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Fieldpoint Private Securities's AIMT Position: Q2 2020 in Review

Fieldpoint Private Securities sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 12,669 shares — an estimated $183K sold.

Fieldpoint Private Securities first reported a position in AIMT in Q3 2019 and held it in 3 quarters. The position peaked at $429K in Q4 2019. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Fieldpoint Private Securities reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Fieldpoint Private Securities sold 12,669 Aimmune Therapeutics shares in Q2 2020, an estimated $183K.
  • Fieldpoint Private Securities first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 3 quarters.
  • Fieldpoint Private Securities's Aimmune Therapeutics position peaked at $429K in Q4 2019.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Fieldpoint Private Securities's 13F filing for Q2 2020, filed 14 Aug 2020.